Regional chemotherapy of maxillofacial malignant melanoma with intracarotid artery infusion of DTIC.
Six intracarotid artery infusions of DTIC were performed in 4 patients with invasive malignant melanoma of the maxillo-facial region. A total dose of 3.5 to 7 g was well tolerated. Only 1 patient who received 9.5 g in 25 days developed a reversible bone marrow depletion. Two out of the 4 patients presented a transient 50% tumor surface regression, but no response was seen after the second infusion. Of the 2 remaining patients, 1 had no measurable effect and 1 experienced tumor progression.
D000368:Aged; D001853:Bone Marrow / Q000187:drug effects; D002339:Carotid Arteries; D003606:Dacarbazine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D005153:Facial Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008441:Maxillary Neoplasms / Q000188:drug therapy*; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D014226:Triazenes / Q000008:administration & dosage*
D014226:Triazenes; D003606:Dacarbazine